Ghassan K. Abou-Alfa
加桑·阿布-阿尔法
MD, MBA
Attending Physician, Gastrointestinal Oncology Service; Professor of Medicine, Weill Cornell Medicine胃肠肿瘤科主治医师，威尔康奈尔医学院医学教授
👥Biography 个人简介
Ghassan K. Abou-Alfa, MD, MBA is an Attending Physician in the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center and a leading expert in hepatobiliary malignancies. He is internationally recognized for his pivotal contributions to the development of targeted therapies in biliary tract cancers (BTC), a group of rare and molecularly heterogeneous tumors. Dr. Abou-Alfa led or co-led key phase III trials in HCC and BTC, including the ClarIDHy trial that established ivosidenib (an IDH1 inhibitor) as a treatment for IDH1-mutant cholangiocarcinoma—the first molecular biomarker-defined therapy approved for this disease. He has championed comprehensive molecular profiling of biliary tract cancers, demonstrating the prevalence of actionable alterations including IDH1 mutations, FGFR2 fusions, HER2 amplifications, and BRAF mutations. Beyond BTC, he was a principal investigator for trials of sorafenib, cabozantinib (CELESTIAL trial in HCC), and durvalumab combinations. Dr. Abou-Alfa is a sought-after educator and has served in leadership positions at ASCO, ESMO, and the Cholangiocarcinoma Foundation.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
ClarIDHy Trial — Ivosidenib in IDH1-Mutant Cholangiocarcinoma
Led the phase III ClarIDHy trial demonstrating that ivosidenib (AG-120), an oral IDH1 inhibitor, significantly improved progression-free survival versus placebo in patients with previously treated IDH1-mutant cholangiocarcinoma, leading to FDA approval and establishing the first molecularly targeted standard of care in this disease.
Molecular Profiling and Biomarker-Driven Therapy in BTC
Advanced the clinical use of comprehensive genomic profiling in biliary tract cancers, characterizing actionable alteration frequencies (IDH1 ~15%, FGFR2 fusions ~15% in intrahepatic CCA, HER2 ~5–20% in gallbladder cancer) and co-designing biomarker-selected trials that have delivered multiple targeted approvals.
Cabozantinib in Advanced HCC — CELESTIAL Trial
Co-led the CELESTIAL phase III trial showing that cabozantinib, a MET/VEGFR2/AXL inhibitor, improved overall survival versus placebo in sorafenib-pretreated advanced HCC, establishing cabozantinib as a second-line standard of care.
Global BTC Trial Leadership and Advocacy
Has served as global principal investigator or steering committee member for more than a dozen biliary tract cancer trials, including ABC-02 (gemcitabine-cisplatin), TOPAZ-1 (durvalumab combination), and numerous targeted therapy studies, systematically building the evidence base for a historically neglected disease.
Representative Works 代表性著作
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy)
The Lancet Oncology (2020)
Phase III trial demonstrating ivosidenib improved PFS vs placebo (2.7 vs 1.4 months; HR 0.37) in IDH1-mutant cholangiocarcinoma, supporting FDA approval.
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
New England Journal of Medicine (2018)
CELESTIAL phase III trial establishing cabozantinib as a second-line standard in advanced HCC with improved OS (10.2 vs 8.0 months; HR 0.76).
Gemcitabine plus cisplatin versus gemcitabine for biliary tract cancer
New England Journal of Medicine (2010)
ABC-02 trial establishing gemcitabine-cisplatin as the first-line standard of care for advanced biliary tract cancer, a regimen that remained standard for over a decade.
Systemic therapy for hepatocellular carcinoma: 2020 update
Annals of Oncology (2020)
Comprehensive review of the expanding systemic therapy landscape for HCC including first- and second-line targeted agents and immunotherapy combinations.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 加桑·阿布-阿尔法 的研究动态
Follow Ghassan K. Abou-Alfa's research updates
留下邮箱，当我们发布与 Ghassan K. Abou-Alfa（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment